ViaCyte Company
ViaCyte is a preclinical therapeutic company specializing in regenerative medicine therapies for diabetes. Their therapy is based on the differentiation of stem cells into pancreatic beta-cell precursors, with subcutaneous implantation in an encapsulation device.
Investors
Founded Date:
1999-01-01
Last Funding Type:
Venture - Series Unknown
Headquarters:
United States
Investors Number:
17
Technology:
Regenerative Medicine
Employee Number:
51-100
Industry:
Metabolism Dysfunctions
Estimated Revenue:
$10M to $50M
Investor Type:
For Profit
Total Funding:
$235.5M